This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Refractory Generalized Anxiety Disorder

Mark H. Pollack, MD

Published: April 15, 2009

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Generalized anxiety disorder (GAD) has a lifetime prevalence in the US population of about 5.7%.Typically, GAD begins in early adulthood and tends to have a chronic and persistent course. The disorderfrequently presents comorbidly with other conditions, and about 90% of patients with GADhave at least 1 comorbid lifetime psychiatric disorder. Patients with GAD tend to be high users ofmedical services; the disorder is associated with significant physical as well as psychological symptomatologyand impacts health, family relationships, and employment. Pharmacologic and psychosocialtreatments are available for GAD.’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 70

Quick Links: Anxiety

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...